Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
- Registration Number
- NCT01606995
- Lead Sponsor
- Bayer
- Brief Summary
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6784
Inclusion Criteria
- Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Rivaroxaban (Xarelto, BAY59-7939) -
- Primary Outcome Measures
Name Time Method Safety variables will be summarized using descriptive statistics based on adverse events collection after 1 year or until 30 days after end of rivaroxaban therapy Adjudicated major bleeding events after 1 year or until 30 days after end of rivaroxaban therapy
- Secondary Outcome Measures
Name Time Method All cause mortality after 1 year or until 30 days after end of rivaroxaban therapy Persistence with rivaroxaban treatment: Reasons for any switch from or interruption of rivaroxaban treatment after 1 year or until 30 days after end of rivaroxaban therapy Adjudicated symptomatic thromboembolic events after 1 year or until 30 days after end of rivaroxaban therapy